[Treatment of airway inflammation in cystic fibrosis].
Cystic fibrosis airway inflammation is characterized by neutrophilic efflux and high levels of proinflammatory cytokines such as IL-8 and IL-6. Inhaled corticosteroids are widely used despite lack of evidence of efficacity. Despite evidence of efficacity of ibuprofen, many clinicians have chosen not to use this therapy because of concerns regarding potential side effects. Azithromycin has antiinflammatory properties and is effective in cystic fibrosis (CF) patients. Deoxyribonuclease (rhDNase) has been shown to improve lung function in patients with cystic fibrosis and may also have a positive effect on inflammation. Other antiinflammatory drugs are in the process of validation.
Abély
M
M
Service de pédiatrie A, centre de ressources et de compétences pour la mucoviscidose, American Memorial Hospital, CHU de Reims, 47, rue Cognacq-Jay, 51092 Reims cedex, France. mabely@chu-reims.fr
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications*; D003850:Deoxyribonuclease I / Q000627:therapeutic use; D004281:Docosahexaenoic Acids / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology; D016753:Interleukin-10 / Q000627:therapeutic use; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D000998:Antiviral Agents; D020024:Leukotriene Antagonists; D011994:Recombinant Proteins; D053481:Secretory Leukocyte Peptidase Inhibitor; D016753:Interleukin-10; D004281:Docosahexaenoic Acids; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I